Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) — Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today with its merger partner, IMAC Holdings, INC (Nasdaq:BACK), announce that the companies have responded to the SEC’s first round of comments on the jointly filed form S-4. A Form S-4 is a registration statement that the Securities and Exchange Commission requires all reporting companies to file in order to publicly offer new securities pursuant to a merger or acquisition. The Companies previously filed the S-4 on September 29th and received comments from the SEC in late October.
Related news for (THER)
- Theralink announces groundbreaking RPPA study by partner GMU – reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
- Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
- Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023
- Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer